Core Insights - The article highlights the increasing federal focus on deep brain neurostimulation as a promising therapy for conditions such as TBI, PTSD, stroke recovery, and Alzheimer's disease, with Nexalin Technology, Inc. playing a significant role in this emerging field [1][4][10] Legislative Developments - Recent bipartisan Congressional initiatives have expanded federal support for deep brain neurostimulation research, particularly through the U.S. Department of Veterans Affairs (VA) and the National Institutes of Health (NIH) [1][4] - H.R. 7091, introduced on January 15, 2026, aims to expand clinical trials for deep brain neurostimulation and establish a compassionate use pathway within the VA system [7] - The Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2026, includes provisions for neuromodulation research focused on stroke recovery among veterans, signed into law by President Trump [7] - The Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026, expands NIH-supported research using deep brain stimulation for Alzheimer's and Parkinson's diseases, also signed into law by President Trump [7] Company Initiatives - Nexalin Technology's DIFS™ technology is recognized as a sophisticated form of non-invasive deep brain neurostimulation and is currently being evaluated in research with UC San Diego and the San Diego VA veterans' community [2][5] - The company is actively engaged in policy advocacy to support the inclusion of deep brain neurostimulation in federal legislation, which has raised awareness of its therapeutic potential among policymakers [8][9] - Nexalin believes that the expanding federal support for neuromodulation research aligns with its strategic focus on developing non-invasive technologies to address significant unmet medical needs [5][9] Market Opportunity - Conditions such as TBI, PTSD, stroke-related neurological impairment, Alzheimer's disease, and Parkinson's disease represent multi-billion-dollar addressable markets with significant unmet medical needs [10] - As federal research initiatives expand, Nexalin is positioned to advance emerging neurostimulation therapies within the VA system and the broader healthcare infrastructure [10][11]

Core Viewpoint - Nexalin Technology, Inc. has successfully closed a public offering of 3,850,000 shares at a price of $1.30 per share, raising approximately $5.0 million in gross proceeds before expenses [1]. Company Overview - Nexalin Technology, Inc. specializes in developing innovative neurostimulation products aimed at addressing the global mental health crisis. The company's products are designed to be non-invasive and are believed to provide relief for mental health issues [5]. - The company utilizes bioelectronic medical technology to treat mental health disorders, with a focus on penetrating deep brain structures associated with these conditions. Nexalin's next-generation devices are expected to enhance patient response without adverse side effects [5]. - The Nexalin Gen-2 15 milliamp neurostimulation device has received approval in China, Brazil, and Oman [5]. Offering Details - The public offering was conducted under an effective shelf registration statement filed with the U.S. Securities and Exchange Commission (SEC) on April 23, 2025, and declared effective on April 29, 2025 [3]. - Maxim Group LLC served as the sole book-running manager for the offering [2].

Company Overview - Nexalin Technology, Inc. is a leader in Deep Intracranial Frequency Stimulation (DIFS™) technology aimed at addressing mental health issues through innovative neurostimulation products [5] - The company's products are designed to be non-invasive and are believed to provide relief for individuals suffering from mental health disorders [5] Public Offering Details - Nexalin announced a public offering of 3,850,000 shares of common stock priced at $1.30 per share, with expected gross proceeds of approximately $5.0 million [1] - The offering is set to close on or about May 6, 2025, subject to customary closing conditions [1] - An additional 577,500 shares may be purchased by underwriters within a 45-day option period at the public offering price [1] Use of Proceeds - The net proceeds from the offering will be utilized for working capital and general corporate purposes, including sales and marketing, product development, and capital expenditures [2] Regulatory Compliance - A shelf registration statement for the shares was filed with the SEC on April 23, 2025, and was declared effective on April 29, 2025 [3] - The offering is being conducted through a written prospectus and prospectus supplement available on the SEC's website [3]